Dendritic cells transfected with Her2 antigen-encoding RNA replicons cross-prime CD8 T cells and protect mice against tumor challenge.
Antigen-specific T cells can be induced by direct priming and cross-priming. To investigate cross-priming as a vaccination approach dendritic cells were transfected with cytopathogenic viral RNA-replicons that expressed domains of the tumor-associated Her2-antigen and injected into MHC-discordant mice that did not allow direct priming. Upon tumor challenge 75% of the vaccinated, but none of the mock-vaccinated mice remained tumor-free. The anti-tumor effect required T cells and correlated with the vigor of the cross-primed CD8 T cell response. Her2-specific antibodies were not detected. This study highlights the potential of T cell cross-priming in cancer immunotherapy.
Edlich
Birgit
B
Institute of Biochemistry and Biotechnology, Faculty of Life Sciences (NFI), Section Microbial Biotechnology, Martin-Luther-University Halle-Wittenberg, Kurt-Mothes-Str. 3, D-06120 Halle/Saale, Germany.
Hogdal
Leah J
LJ
Rehermann
Barbara
B
Behrens
Sven-Erik
SE
D000818:Animals; D000912:Antibodies, Neoplasm / Q000097:blood; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology*; D045744:Cell Line, Tumor; D045142:Cross-Priming; D003713:Dendritic Cells / Q000276:immunology*; D007167:Immunotherapy; D018664:Interleukin-12 / Q000276:immunology; D051379:Mice; D012313:RNA / Q000235:genetics; D051381:Rats; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000276:immunology*; D012093:Replicon; D014162:Transfection
D000912:Antibodies, Neoplasm; D019496:Cancer Vaccines; D018664:Interleukin-12; D012313:RNA; D018719:Erb-b2 Receptor Tyrosine Kinases; C483804:Erbb2 protein, rat